high response rate when using a bispecific antibody to treat R/R multiple myeloma.

Published Date: 12 Apr 2024

71 percent ORR that increased over time, along with a good safety record when using linvoseltamab.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New guidelines for radiation therapy for HPV-associated head and neck cancer

2.

Review looks at potential treatment targets in the tumor microenvironment.

3.

Even when they are not paying attention, children are still learning.

4.

The Benefits of Exercise for Substance Use Disorders.

5.

The top three drugs for multiple myeloma treatment upfront are four.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot